雄激素剥夺疗法的使用与前列腺癌患者心力衰竭风险：一项系统评价和荟萃分析。
Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.
作者信息
Khorram Amir Alinejad, Pourasgharian Reyhaneh, Shams Ali Samadi, Toufani Shahin, Mostafaei Mehrsa, Khademi Reza, Daghayeghi Reza, Valifard Maryam, Shahrokhi Mehregan, Seyedipour Sina, Deravi Niloofar, Naziri Mahdyieh, Malek Mahta, Bashir Faizan
机构信息
Urology Department, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
BMC Cardiovasc Disord. 2024 Dec 30;24(1):756. doi: 10.1186/s12872-024-04421-w.
BACKGROUND & AIM: We aimed in this study to investigate the relationship between Androgen Deprivation Therapy (ADT) use and the risk of heart failure in patients with prostate cancer. In this research, the negative or positive effects of ADT in the development of cardiovascular diseases or its exacerbation in people with prostate cancer have been investigated.
MATERIALS AND METHODS
For this research, we reviewed articles from PubMed, Scopus, and Google Scholar databases until February 2024. We extracted and screened titles, abstracts, and full texts of related articles. The quality of studies was assessed and extracted and analyzed data.
RESULT
A total of 9 studies comprising 189,045 patients were included in the meta-analysis, examining the association between androgen deprivation therapy (ADT) and heart failure. The overall pooled hazard ratio (HR) was 1.299 (95% CI: 1.003-1.595), indicating a significantly increased risk of heart failure with ADT. Subgroup analyses revealed that the risk was stronger in Asian populations (pooled HR = 1.545, 95% CI: 1.180-1.910) compared to North American populations (pooled HR = 0.779, 95% CI: 0.421-1.138).
CONCLUSIONS
ADT has a significant relationship with cardiovascular disease. According to the analysis, ADT has increased the risk of heart failure in people with prostate cancer by 30%.
背景与目的
本研究旨在调查雄激素剥夺疗法（ADT）的使用与前列腺癌患者心力衰竭风险之间的关系。在这项研究中，研究了ADT在心血管疾病发生或前列腺癌患者病情加重方面的负面或正面影响。
材料与方法
在本研究中，我们检索了截至2024年2月来自PubMed、Scopus和谷歌学术数据库的文章。我们提取并筛选了相关文章的标题、摘要和全文。评估了研究质量，并对提取和分析的数据进行了处理。
结果
共有9项研究（涉及189,045名患者）纳入荟萃分析，研究雄激素剥夺疗法（ADT）与心力衰竭之间的关联。总体合并风险比（HR）为1.299（95%置信区间：1.003 - 1.595），表明ADT使心力衰竭风险显著增加。亚组分析显示，与北美人群（合并HR = 0.779，95%置信区间：0.421 - 1.138）相比，亚洲人群的风险更高（合并HR = 1.545，95%置信区间：1.180 - 1.910）。
结论
ADT与心血管疾病存在显著关系。根据分析，ADT使前列腺癌患者的心力衰竭风险增加了30%。
Zotero 插件